14 December, 2016 by The TZ Newswire Staff Comments Off on Stratfor: How 2017 is likely to be a turning point away from the eurozone
Stratfor: How 2017 is likely to be a turning point away from the eurozone
Since financial, economic and political crises descended on the Continent almost a decade ago, Europe has endured many difficult moments.
14 December, 2016 by The TZ Newswire Staff Comments Off on Outside the Box: Look beyond the DJIA, S&P 500 records, and this has been a 3-year ‘Seinfeld market’
Outside the Box: Look beyond the DJIA, S&P 500 records, and this has been a 3-year ‘Seinfeld market’
For those who diversified in stocks, bonds and globally, returns have largely been about nothing.
read more
14 December, 2016 by The TZ Newswire Staff Comments Off on Tradency Teams Up with NPBFX to Offer RoboX Smart Trading
Tradency Teams Up with NPBFX to Offer RoboX Smart Trading
NPBFX is the second brokerage this week to have joined the growing global trend of RoboX.
14 December, 2016 by The TZ Newswire Staff Comments Off on 4 Things PotashCorp CEO Wants You to Know for 2017
4 Things PotashCorp CEO Wants You to Know for 2017
14 December, 2016 by The TZ Newswire Staff Comments Off on This Israeli Starbucks Competitor Is Pumping Out $1 Cappuccinos
This Israeli Starbucks Competitor Is Pumping Out $1 Cappuccinos
Starbucks Corporation’s (NASDAQ:SBUX) biggest threat to global coffee dominance might be an Israeli-based barebones coffee chain intent on bringing ultra cheap java to the masses.
14 December, 2016 by The TZ Newswire Staff Comments Off on Uber self-driving cars hit the streets of San Francisco
Uber self-driving cars hit the streets of San Francisco
The Uber self-driving cars will be put to the test in the congested streets of San Francisco.
14 December, 2016 by The TZ Newswire Staff Comments Off on Washington Cuts a Check to Spark Healthcare Innovation
Washington Cuts a Check to Spark Healthcare Innovation
The 21st Century Cures Act aims to ignite innovation with perks to biopharma and medical device makers that could increase drug and device development, shrink regulation, and accelerate how quickly new treatments make it to market. Will the 21st Century Cure Act be a boon to investors in drug and medical device stocks?